In the present study, we evaluated the value of computed tomography-guided 125I implantation for malignant osseous tumors.
Methods
Under computed tomography guidance, 125I seeds were implanted into malignant osseous tumors of 19 patients. The curative effect was evaluated according to the degree of ostealgia relief and the changes in radiological images.
Results
The 125I seeds were implanted successfully in all 19 cases. No complication was observed. Pain relief was obtained in 17 of the 19 malignant osseous tumor patients after implantation, and the effective rate was 89.5%. Follow-up computed tomography reexamination at 1, 2 and 6 months demonstrated that of the 25 lesions in 19 cases, obvious relief was obtained in 2, partial relief in 15, a slight decrease in 7, and a progressive decrease in 1. The response rate was 68%.
Conclusions
Computed tomography-guided 125I implantation is a safe, effective and feasible method in the treatment of patients with malignant osseous tumors.
WhitomoreWFJr., HilarisB., GrabstaldH.: Retropublic implantation of iodine 125 in the treatment of prostatic cancer. J Urol, 108: 918–920, 1972.
2.
LangleyS.E.M., LaingR.W.: Iodine seed prostate brachytherapy: an alternative first-line choice for early prostate cancer. Prostate Cancer Prostatic Dis, 7: 201–207, 2004.
3.
JansenN., DeneufbourgJ.M., NickersP.: Adjuvant stereotactic permanent seed breast implant: a boost series in view of partial breast irradiation. Int J Radiat Oncol Biol Phys, 67: 1052–1058, 2007.
4.
FrankS.J., PistersL.L., DavisJ., LeeA.K., BassettR., KubanD.A.: An assessment of quality of life following radical prostatectomy, high dose external beam radiation therapy and brachytherapy iodine implantation as monotherapies for localized prostate cancer. J Urol, 177: 2151–2156, 2007.
5.
BladouF., ThuretR., GravisG., KarsentyG., SermentG., SalemN.: Techniques, indications and results of permanent prostate brachytherapy for localized prostate cancer. Ann Urol (Paris), 41: 68–79, 2007.
6.
AshD., Al-QaisiehB., BottomleyD., CareyB., JosephJ.: The impact of hormone therapy on post-implant dosimetry and outcome following Iodine-125 implant monotherapy for localised prostate cancer. Radiother Oncol, 75: 303–306, 2005.
7.
MooreM.J.: Pancreatic cancer: what the oncologist can offer for palliation. Can J Gastroenterol, 16: 121–124, 2012.
8.
KornekG.V., Schratter SehnA., MarczellA., DepischD., KarnerJ., HaiderK., KwasnyW., LockerG., ScheithauerW.: Treatment of unresectable, locally advanced pancreatic adenocarcinoma with combined radiochemotherapy with 5-fluorouracil, leucovorin and cisplatin. Br J Cancer, 82: 98–103, 2000.
9.
MutignaniM., ShahS.K., MorgantiA.G.: Treatment of unresectable pancreatic carcinoma by intraluminal brachytherapy in the duct of Wirsung. Endoscopy, 34: 555–559, 2002.
10.
ZhaoE., ManS., QinY.: Permanent interstitial implantation of 1211 seeds for 5 cases of advanced head and neck cancer. Lin Chuang Er Bi Yan Hou Ke Za Zhi, 18: 348–352, 2004.
11.
VideticG.M., GasparL.E., ZamoranoL., StittL.W., FontanesiJ., LevinK.J.: Implant volume as a prognostic variable in brachytherapy decision-making for malignant gliomas stratified by the RTOG recursive partitioning analysis. Int J radiat Oncol Biol Phys, 51: 963–968, 2001.
12.
JulowJ., SzeifertG.T., BálintK., NyaryI., NemesZ.: The role of microglia/macrophage system in the tissue response to I-125 interstitial brachytherapy of cerebral gliomas. Neurol Res, 29: 233–238, 2007.
13.
JulowJ., SzeifertG.T., BálintK., NyaryI., NemesZ.: Tissue response to iodine-125 interstitial brachytherapy of cerebral gliomas. Prog Neurol Surg, 20: 312–323, 2007.
14.
MaldeR., AgarwalJ.P., LaskarS.G., GuptaT., DinshawK.: High dose rate brachytherapy boost for primary nasopharyngeal carcinoma: preliminary results of an ongoing prospective study. Bull Cancer, 92: E45–50, 2005.
15.
JohnsonM., ColoniasA., PardaD., TrombettaM., GayouO., ReitzB., MiftenM.: Dosimetric and technical aspects of intraoperative I-125 brachytherapy for stage I non-small cell lung cancer. Phys Med Biol, 52: 1237–1245, 2007.
16.
MartinezM.R., NagS., NierodaC.A., MartinE.W.: Iodine-125 brachytherapy in the treatment of colorectal adenocarcinoma metastatic to the liver. Cancer, 85: 1218–1225, 1999.
17.
SnojM., RudolfZ., CemazarM.: Successful sphincter-saving treatment of anorectal malignant melanoma with electrochemotherapy, local excision and adjuvant brachytherapy. Anticancer Drugs, 16: 345–348, 2005.
18.
LiD.F., CuiQ., WangQ., SuH., ZhangW.J., ZhangP., ZhouJ., SuiJ.H., ZengY.J.: Application of I(125) brachytherapy combined artificial joint prosthesis in malignant osteo- and soft-tissue sarcoma. Cancer Biother Radiopharm, 21: 167–172, 2006.
19.
Martinez-MongeR., Perez-OchoaA., San JulianM., AguerretaD., SierrasesumagaL.: Bone HDR brachytherapy in a patient with recurrent Ewing's sarcoma of the acetabulum: alternative to aggressive surgery. Brachytherapy, 2: 114–116, 2003.
20.
RogersC.L., TheodoreN., DickmanC.A., SonntagV.K., ThomasT., LamS., SpeiserB.L.: Surgery and permanent 125I seed paraspinal brachytherapy for malignant tumors with spinal cord compression. Int J Radiat Oncol Biol Phys, 54: 505–513, 2002.
21.
ZhangF., WuP., LuM.: Application of 125I seed permanent plantation in osseous metastases. Chin J Radiol, 41: 76–78, 2003.
22.
MatsumineA., KusuzakiK., MatsubaraT, ShintaniK., SatonakaH., WakabayashiT., MiyazakiS., MoritaK., TakegamiK., UchidaA.: Novel hyperthermia for metastatic bone tumors with magnetic materials by generating an alternating electromagnetic field. Clin Exp Metastasis, 24: 191–200, 2007.
23.
ChowE., HarrisK., FanG., TsaoM., SzeW.M.: Palliative radiotherapy trials for bone metastases: a systematic review. J Clin Oncol, 25: 1423–1436, 2007.
24.
SmithW.L., LewisC., BaumanG., RodriguesG., D'SouzaD., AshR., HoD., VenkatesanV., DowneyD., FensterA.: Prostate volume contouring: a 3D analysis of segmentation using 3DTRUS, CT, and MR. Int J Radiat Oncol Biol Phys, 67: 1238–1247, 2007.
25.
RosenG., TanC., SanmaneechaiA., BeattieE.J., MarcoveR., MurphyM.L.: The rationale for multiple drug chemotherapy in the treatment of osteogenic sarcoma. Cancer, 35(3 Suppl): 936–945, 1975.
26.
WafaH., GrimerR.J.: Surgical options and outcomes in bone sarcoma. Expert Rev Anticancer Ther, 6: 239–248, 2006.
27.
GersztenP.C., BurtonS.A., OzhasogluC., WelchW.C.: Radiosurgery for spinal metastases: clinical experience in 500 cases from a single institution. Spine, 32: 193–199, 2007.
28.
RivardM.J., ButlerW.M., DevlinP.M., HayesJ.K., HearnR.A., LiefE.P., MeigooniA.S., MerrickG.S., WilliamsonJ.F.: American Brachytherapy Society recommends no change for prostate permanent implant dose prescriptions using iodine-125 or palladium-103. Brachytherapy, 6: 34–37, 2007.
29.
RogersC.L., TheodoreN., DickmanC.A., SonntagV.K., ThomasT., LamS., SpeiserB.L.: Surgery and permanent 125I seed paraspinal brachytherapy for malignant tumors with spinal cord compression. Int J Radiat Oncol Biol Phys, 54: 505–513, 2007.
30.
ObinataK., OhmoriK., TuchiyaK., NishiokaT., ShiratoH., NakamuraM.: Clinical study of a spacer to help prevent osteoradionecrosis resulting from brachytherapy for tongue cancer. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 95: 246–250, 2003.
31.
ReedD.R., WallnerK., FordE., MuellerA., MerrickG., MakiJ., SutliefS., ButlerW.: Effect of post-implant edema on prostate brachytherapy treatment margins. Int J Radiat Oncol Biol Phys, 63: 1469–1473, 2005.
32.
FukadaJ., YorozuA., ToyaK., OhashiT., SugawaraA., DokiyaT.: Pulmonary embolization of permanently implanted radioactive iodine-125 seeds for carcinoma of the prostate. Nippon Igaku Hoshasen Gakkai Zasshi, 65: 121–123, 2005.
33.
TsuiG., GillanC., PondG., CattonC., CrookJ.: Posttreatment complications of early stage prostate cancer patients: brachytherapy versus three-dimensional conformal radiation therapy. Cancer J, 11: 122–132, 2005.
